One such clinical trial (ICORG10–05/NCT01485926) was a phase II neoadjuvant study assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in early stage HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast cancer.